{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:41:56Z","timestamp":1789465316610,"version":"build-2803163510"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,15]]},"DOI":"10.1093\/ejhf\/xuag204","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:35:59Z","timestamp":1782214559000},"page":"343-346","source":"Crossref","is-referenced-by-count":0,"title":["What\u2019s new in heart failure? June 2026"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5043-8520","authenticated-orcid":false,"given":"Philipp","family":"Markwirth","sequence":"first","affiliation":[{"name":"Department of Internal Medicine III, Saarland University Hospital , Homburg ,","place":["Germany"]},{"name":"HOMICAREM (HOMburg Institute for CArdioREnalMetabolic Medicine), Saarland University , Homburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2023-3026","authenticated-orcid":false,"given":"Julian","family":"Hoevelmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Saarland University Hospital , Homburg ,","place":["Germany"]},{"name":"Cape Heart Institute, Faculty of Health Sciences, University of Cape Town , Cape Town ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6059-1671","authenticated-orcid":false,"given":"Mert","family":"Tokcan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Saarland University Hospital , Homburg ,","place":["Germany"]},{"name":"HOMICAREM (HOMburg Institute for CArdioREnalMetabolic Medicine), Saarland University , Homburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6109-431X","authenticated-orcid":false,"given":"Bernhard","family":"Haring","sequence":"additional","affiliation":[{"name":"HOMICAREM (HOMburg Institute for CArdioREnalMetabolic Medicine), Saarland University , Homburg ,","place":["Germany"]},{"name":"Department of Medicine IV, Clinic Hietzing , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"2026091504190137000_xuag204-B1","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/ejhf\/xuag114","article-title":"Hemodynamic changes in response to GLP-1 treatment in ICD and CRT patients: insights from HeartLogic sensor data","volume":"28","author":"Fussing","year":"2026","journal-title":"Eur J Heart Fail"},{"key":"2026091504190137000_xuag204-B2","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"2026091504190137000_xuag204-B3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026091504190137000_xuag204-B4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2337\/dc16-1580","article-title":"Effects of liraglutide on heart rate and heart rate variability: a randomized, double-blind, placebo-controlled crossover study","volume":"40","author":"Kumarathurai","year":"2017","journal-title":"Diabetes Care"},{"key":"2026091504190137000_xuag204-B5","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/s0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"2026091504190137000_xuag204-B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.102573","article-title":"Effects of glucagon-like peptide 1 receptor agonist initiation in patients with heart failure with reduced ejection fraction and implantable cardiac devices","volume":"13","author":"Marques","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026091504190137000_xuag204-B7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ejhf.3024","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"26","author":"McDonagh","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026091504190137000_xuag204-B8","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026091504190137000_xuag204-B9","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","article-title":"Results of the randomized aldosterone antagonism in heart failure with preserved ejection fraction trial (RAAM-PEF)","volume":"17","author":"Deswal","year":"2011","journal-title":"J Card Fail"},{"key":"2026091504190137000_xuag204-B10","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.amjcard.2012.05.049","article-title":"Usefulness of matrix metalloproteinase-9 plasma levels to identify patients with preserved left ventricular systolic function after acute myocardial infarction who could benefit from eplerenone","volume":"110","author":"Kampourides","year":"2012","journal-title":"Am J Cardiol"},{"key":"2026091504190137000_xuag204-B11","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/ejhf.3266","article-title":"Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF trial","volume":"26","author":"Solomon","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026091504190137000_xuag204-B12","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026091504190137000_xuag204-B13","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/ejhf\/xuag083","article-title":"Finerenone, eplerenone, and spironolactone in heart failure with preserved ejection fraction: a Bayesian network meta-analysis of efficacy and safety","volume":"28","author":"Bagattoli","year":"2026","journal-title":"Eur J Heart Fail"},{"key":"2026091504190137000_xuag204-B14","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/s0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"},{"key":"2026091504190137000_xuag204-B15","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026091504190137000_xuag204-B16","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026091504190137000_xuag204-B17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf788","article-title":"Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients","author":"Wu","year":"2025","journal-title":"Eur Heart J"},{"key":"2026091504190137000_xuag204-B18","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/ejhf\/xuag054","article-title":"Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-pooled analysis","volume":"28","author":"Ferreira","year":"2026","journal-title":"Eur J Heart Fail"},{"key":"2026091504190137000_xuag204-B19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/ejhf\/xuag097","article-title":"Genitourinary tract infections in SGLT2 inhibitors treated heart failure patients","volume":"28","author":"Marx-Sch\u00fctt","year":"2026","journal-title":"Eur J Heart Fail"},{"key":"2026091504190137000_xuag204-B20","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026091504190137000_xuag204-B21","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/ejhf\/xuag071","article-title":"Are \u03b2-blockers necessary for patients with heart failure with preserved ejection fraction? PURSUIT-HFpEF registry","volume":"28","author":"Nishino","year":"2026","journal-title":"Eur J Heart Fail"},{"key":"2026091504190137000_xuag204-B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.16598","article-title":"Association of \u03b2-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial","volume":"2","author":"Silverman","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2026091504190137000_xuag204-B23","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jchf.2023.03.017","article-title":"Beta-blocker use and heart failure outcomes in mildly reduced and preserved ejection fraction","volume":"11","author":"Arnold","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026091504190137000_xuag204-B24","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.cardfail.2021.04.015","article-title":"Association between \u03b2-blockers and outcomes in heart failure with preserved ejection fraction: current insights from the SwedeHF registry","volume":"27","author":"Meyer","year":"2021","journal-title":"J Card Fail"},{"key":"2026091504190137000_xuag204-B25","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/eurheartj\/ehq426","article-title":"Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment","volume":"32","author":"Borlaug","year":"2011","journal-title":"Eur Heart J"},{"key":"2026091504190137000_xuag204-B26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/ejhf.3107","article-title":"Effect of paced heart rate on quality of life and natriuretic peptides for stage B or C heart failure with preserved ejection fraction: a secondary analysis of the myPACE trial","volume":"26","author":"de la Espriella","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026091504190137000_xuag204-B27","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/ejhf\/xuag087","article-title":"The \u03b2-blockers dilemma in HFpEF: indicated, inert, or harmful?","volume":"28","author":"Monzo","year":"2026","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag204\/68609030\/xuag204.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/3\/343\/68609030\/xuag204.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/3\/343\/68609030\/xuag204.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:23:56Z","timestamp":1789460636000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/28\/3\/343\/8715897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6,25]]},"published-print":{"date-parts":[[2026,9,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ejhf\/xuag204","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]}}}